Jump to main content
Jump to site search

Issue 32, 2014
Previous Article Next Article

Nucleic acid therapeutics: basic concepts and recent developments

Author affiliations

Abstract

Nucleic acid based therapeutics have an allure for medicinal chemists due to their potential for specific control of gene expression. Persistent efforts have resulted in the FDA approval of the nucleic acid based drugs Vitravene™, Macugen™ and recently Kynamro™, leading to a sudden leap in the number of active clinical trials involving the nucleic acid moieties. Beginning with antigene and antisense technology, nucleic acid therapeutics have recently gained more potent strategies, e.g. RNA interference, ribozymes, decoy oligonucleotides and aptamers. Nucleic acid based therapeutics which have opened up new frontiers in medicinal chemistry research, along with various chemical modifications undertaken to improve their utility and their mechanism of action, will be discussed in this review article.

Graphical abstract: Nucleic acid therapeutics: basic concepts and recent developments

Back to tab navigation

Publication details

The article was received on 20 Dec 2013, accepted on 13 Mar 2014 and first published on 17 Mar 2014


Article type: Review Article
DOI: 10.1039/C3RA47841F
Citation: RSC Adv., 2014,4, 16618-16631
  •   Request permissions

    Nucleic acid therapeutics: basic concepts and recent developments

    V. K. Sharma, P. Rungta and A. K. Prasad, RSC Adv., 2014, 4, 16618
    DOI: 10.1039/C3RA47841F

Search articles by author

Spotlight

Advertisements